3-甲基哌啶-3-羧酸盐酸盐 | 116140-22-8

• 中文名称: 3-甲基哌啶-3-羧酸盐酸盐
• 英文名称: chlorhydrate de l'acide methyl-3 nipecotique
• 英文别名: 3-Methylpiperidine-3-carboxylic acid hydrochloride；3-methylpiperidine-3-carboxylic acid;hydrochloride
• CAS: 116140-22-8
• 化学式: C₇H₁₃NO₂*ClH
• mdl: MFCD20441739
• 分子量: 179.647
• InChiKey: KSMYDSAXTLQXCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.88
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P270,P301+P312+P330,P501
• 危险性描述：
  H302

反应信息

• 作为产物：
  描述：

  3-哌啶甲酸乙酯 在 盐酸 、 sodium hydroxide 、 正丁基锂 、 三乙胺 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 水 为溶剂， 反应 9.0h， 生成 3-甲基哌啶-3-羧酸盐酸盐
  参考文献：
  名称：

  Dérivés alkylés et arylés de l'acide nipécotique: synthèse et appréciation de l'activité inhibitrice de la capture du GABA en fonction de paramètres conformationnels et de biodisponibilité

  摘要：

  DOI：

  10.1016/0223-5234(87)90025-0

文献信息

• TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1165540A1

  公开（公告）日：2002-01-02
• N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
  申请人：Novartis AG

  公开号：EP3921313A1

  公开（公告）日：2021-12-15
• US6458830B1
  申请人：——

  公开号：US6458830B1

  公开（公告）日：2002-10-01
• [EN] TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] DERIVES DE TETRAHYDROPYRANE ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2000056727A1

  公开（公告）日：2000-09-28

  The present invention relates to compounds of formula (I) wherein: R?1, R2, R3, R4, R5, R9 and R10¿ represent a variety of substituents; R6 represents hydrogen or a C¿1-4?alkyl group optionally substituted by a hydroxy group; R?7¿ represents halogen, hydroxy, optionally substituted C¿2-4?alkenyl, optionally substituted C2-4alkynyl, N3, -NR?11R12, -NRaCORb¿, -OSO¿2R?a, -(CH¿2?)pNR?a(CH¿2)qCOOR?b, CORa, COORa¿, -N=C=O, or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S which heteroaromatic ring is optionally substituted at any substitutable position by a substituent selected from =O, =S, halogen, hydroxy, -SH, CORa, CO2R?a, -ZNR11R12, C¿1-4alkyl, hydroxyC1-4alkyl, fluoroC1-4alkyl, chloroC1-4alkyl, C1-4alkoxy, fluoroC1-4alkoxy or C1-4alkoxy substituted by a C1-4alkoxy or hydroxyl group; R8 represents hydrogen, C¿1-6?alkyl, fluoroC1-6alkyl, hydroxy, C1-6alkoxy or hydroxyC1-6alkyl; and n is zero, 1 or 2; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
• [EN] N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS DE N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE
  申请人：NOVARTIS AG

  公开号：WO2020161623A1

  公开（公告）日：2020-08-13

  The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.